Parkinson's News Today

The Parkinson's Foundation reports that every year, between 50,000 and 60,000 new cases of Parkinson's disease (PD) are identified in the U.S., adding to the existing one million individuals living with this condition. Parkinson's News Today is a daily online publication focused on delivering news about the science, research, and advocacy related to Parkinson's disease. Our writing team consists of both PhDs and experienced journalists, enabling us to present scientific information in a way that is accessible and easy for patients to comprehend.

Consumer

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#564311

United States

#173172

Health/Health Conditions and Concerns

#432

Traffic sources

Monthly visitors

Articles

Was loss of smell one of Dad’s first Parkinson’s symptoms?

4 days ago | parkinsonsnewstoday.com | Mary Beth Skylis

Many years ago, my dad began to lose his sense of smell. A doctor told him that it was likely because of his nasal polyps — small, noncancerous growths that can be caused by long-term inflammation. These polyps are relatively common, affecting up to 40% of the U.S. population, and can lead to complications if left untreated. After careful consideration, Dad decided to get the polyps surgically removed. However, he regained little, if any, sense of smell after the procedure.
Dosing begins in Parkinson’s clinical trial of brain-penetrant therapy

4 days ago | parkinsonsnewstoday.com | Margarida Maia

The first patient has been dosed in a pivotal Phase 2/3 clinical trial testing BHV-8000, a brain-penetrant oral small molecule that Biohaven Therapeutics is developing as a disease-modifying therapy for neuroinflammatory conditions, including Parkinson’s disease. The clinical trial (NCT06976268) is evaluating the effectiveness and safety of BHV-8000 in individuals with early Parkinson’s disease.
Study reinforces inflammation's role in Parkinson's development

6 days ago | parkinsonsnewstoday.com | Andrea Lobo

Microglia-driven inflammation plays an early, key role in the development of neurodegenerative diseases, including Parkinson’s disease, by contributing to the spread of abnormal protein clumps in the brain. That’s according to study results published by a team of South Korean researchers and highlighted by Zyversa Therapeutics, which recently published data showing IC 100, its experimental therapy for Parkinson’s, prevented the activation of inflammatory pathways in microglia.
Apathy treatment IRL757 found safe in multiple doses

1 week ago | parkinsonsnewstoday.com | Andrea Lobo

Multiple doses of apathy treatment IRL757 for Parkinson’s disease and other neurological disorders were well tolerated and presented a favorable pharmacological profile in the second part of a Phase 1 trial. This part of the Phase 1 clinical trial (NCT06493045) tested the safety and tolerability of multiple ascending doses of the Irlab Therapeutics treatment in healthy volunteers.
Gene therapy tool reaches brain structures affected in Parkinson’s

1 week ago | parkinsonsnewstoday.com | Margarida Maia

A gene therapy tool dubbed AAV-DB-3, being developed by Latus Bio to deliver therapeutic genetic material into cells, is able to reach deep structures in the brain — among them ones that become damaged in neurodegenerative disorders such as Parkinson’s disease — a study in mice, monkeys, and lab-grown human cells has found. According to the researchers, these findings show the experimental tool may advance gene therapies for Huntington’s disease and Parkinson’s.
Both Parkinson's patients and partners affected by REM sleep behavior disorder

1 week ago | parkinsonsnewstoday.com | Margarida Maia

REM sleep behavior disorder (RBD) can mean restless nights for people with Parkinson’s disease and their partners, and add to symptoms, such as cognitive impairment and problems with blood pressure or digestion, that make daily life more difficult for both, a study shows.
Phase 3 program for Parkinson's therapy risvodetinib gets FDA review

1 week ago | parkinsonsnewstoday.com | Margarida Maia

Risvodetinib, an experimental oral small molecule Abli Therapeutics is developing for people with untreated Parkinson’s disease, may be one step closer to Phase 3 clinical testing, following a meeting with U.S. regulators. The end-of-Phase 2 meeting’s main goal with the U.S. Food and Drug Administration (FDA) was to define the outcome measures for a Phase 3 study and to see if any more information is needed to file a new drug application, according to a company press release.
Parkinson's gene therapy safe, appears to ease motor symptoms

1 week ago | parkinsonsnewstoday.com | Marisa Wexler

Treatment with Askbio‘s gene therapy candidate AB-1005 is safe and appears to ease motor symptoms in people with either a recent or a long-standing diagnosis of Parkinson’s disease. That’s according to the full results of a small Phase 1 clinical trial conducted by the gene therapy’s developer at three sites in the U.S.Based on the positive data from that Phase 1 study, Askbio is now running a Phase 2 clinical trial called REGENERATE-PD (NCT06285643).
Montara gets grant to develop LRRK2 inhibitor drug for Parkinson's

2 weeks ago | parkinsonsnewstoday.com | Andrea Lobo

The Michael J. Fox Foundation (MJFF) has awarded a $3.3 million research grant to Montara Therapeutics to develop a brain-selective therapy for Parkinson’s disease using the company’s Brainonly platform. As part of the project, Montara will design and develop an LRRK2 inhibitor drug candidate that can reach the brain and avoid the adverse effects typically associated with blocking LRRK2 in peripheral organs, such as the lungs and kidneys.
Small molecule blocking cell death may be used in Parkinson’s

2 weeks ago | parkinsonsnewstoday.com | Margarida Maia

A small molecule that blocks the interaction between two proteins could help protect nerve cells from premature death in neurodegenerative diseases such as Parkinson’s, a study found.